ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
(Thomson Reuters ONE) -
Key updates
* QR-010 was observed to be safe and well-tolerated across all doses in this
trial with no serious adverse events related to treatment.
* A clinically meaningful improvement of CF respiratory symptoms, as measured
by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a mean
improvement of 13.0 to 19.2 points compared to placebo. In a pre-defined
subgroup of subjects with a lower lung function at baseline, the mean
improvement was up to 27.5 points compared to placebo.
* Magnitude of the benefit observed in CFQ-R RSS for these dose groups
exceeded the established minimal clinically important difference of 4.0
points.
* In the same multiple dose groups a supportive trend of improved lung
function was observed up to 4.0% mean absolute change in ppFEV1compared to
placebo. In a pre-defined subgroup of subjects with a lower lung function at
baseline a mean absolute change in ppFEV1 was observed up to 10.9% compared
to placebo.
* After inhaled administration in some dose groups, QR-010 was detected in the
blood.
* ProQR and the Cystic Fibrosis Foundation Therapeutics intend to expand their
partnership to explore the inhaled oligonucleotide platform to target stop-
codon mutations in CF.
* Management will discuss the top-line results during a conference call today
at 5 pm ET.
LEIDEN, the Netherlands, Sept. 25, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics
N.V. (Nasdaq:PRQR) today announced positive preliminary top-line results from a
Phase 1b safety and tolerability clinical trial (Study PQ-010-001; NCT02532764)
of QR-010, a novel investigational RNA therapeutic in subjects with cystic
fibrosis (CF). Full data from the trial will be presented at the North American
CF Conference (NACFC) on November 2-4, 2017.
Study PQ-010-001 was a Phase 1b, randomized, double-blind, placebo-controlled,
dose escalation study to evaluate the safety, tolerability and pharmacokinetics
of QR-010 in adult subjects with CF homozygous for the F508del mutation. This
trial studied 4 dose levels of QR-010 administered via inhalation in 4 single-
dose and 4 multiple-dose groups. A number of exploratory efficacy endpoints were
assessed in the multiple dose groups: respiratory symptoms (as measured by a
validated patient-reported outcome tool, the Cystic Fibrosis Questionnaire-
Revised Respiratory Symptom Score, or CFQ-R RSS), lung function (as measured by
mean absolute change in percent predicted forced expiratory volume in 1 second,
or ppFEV1), sweat chloride test and weight change. This study included subjects
with, on average, a normal lung function at baseline (mean ppFEV1 86%, range
69-116%). As therapeutic trials typically study subjects with normal-to-severe
lung function at baseline (ppFEV1 <90%), a subgroup was pre-defined to analyze
the exploratory efficacy endpoints in this population. The trial recruited 70
participants and was conducted at 23 sites in 10 countries in Europe and North
America.
J. Stuart Elborn, the principal investigator of the study, Clinical Chair in
Respiratory Medicine at Imperial College, Consultant at Royal Brompton Hospital,
and immediate past-president of the European Cystic Fibrosis Society, added,
"QR-010 exceeded expectations in this study as an innovative investigational
therapy for the treatment of cystic fibrosis for which the need remains high.
The improvements demonstrated in reduction of respiratory symptoms are very
encouraging and intriguing and of course of enormous importance to people with
CF. The results of this study together with the previous proof of concept study
are strongly supportive of the further development of QR-010."
Top-Line Results
In this trial QR-010 was observed to be safe and well-tolerated across all
doses, with an overall safety profile similar to placebo. There were no serious
adverse events related to treatment. After inhaled administration in some dose
groups, QR-010 was detected in the blood. Subjects who received QR-010 in the
6.25, 12.5 and 25 mg multiple dose groups reported fewer respiratory symptoms
after 4 weeks of treatment as measured by the increased CFQ-R RSS, with mean
improvements of 13.0, 19.2 and 14.3 points, respectively, compared to placebo.
The effect was more pronounced in the pre-defined subgroup of subjects with a
lower lung function at the start of the study (baseline ppFEV1 70-90%) with a
mean increase of up to 27.5 points compared to placebo. These improvements
exceeded the minimal clinically important difference (MCID) of 4.0 points. A
supportive trend of improved lung function was observed in the same multiple
dose groups, as measured by mean absolute change in ppFEV1 compared to placebo.
The trend was stronger in the subgroup of subjects with a lower lung function at
baseline. The table below summarizes the data per multiple dose group. As
expected, no effect was observed on sweat chloride and weight.
------------------------------------------------------------------------------------------------------------------
Pre-defined subgroup of subjects with
Per protocol population baseline ppFEV1 70-90%
------------------------------------------------ -------------------------------------------------
CFQ-R RSS ppFEV1 CFQ-R RSS ppFEV1
--------- --- -------------------- ------------------- --- -------------------- --------------------
n 95% mean 95% n 95% mean 95% CI
CI absolute CI CI absolute
mean % mean %
Groups change change change change
(12 vs vs vs vs
doses placebo placebo placebo placebo
over 4 (p- (p- (p- (p-
weeks) value) value) value) value)
--------- --- ---------- ------- ---------- ------ --- ---------- ------- ---------- -------
-0.5 -6.0
+13.0 ; +1.2 ; +23.2 2.4 ; +8.0 -3.6 ;
6.25 mg 6 (0.0585) 26.4 (0.7266) 8.4 3 (0.0315) 44.1 (0.1613) 19.5
--------- --- ---------- ------- ---------- ------ --- ---------- ------- ---------- -------
-3.2
+19.2 5.7 ; +4.0 ; +27.5 7.9 ; +10.9 0.2 ;
12.5 mg 6 (0.0072) 32.7 (0.2626) 11.2 4 (0.0095) 47.1 (0.0461) 21.6
--------- --- ---------- ------- ---------- ------ --- ---------- ------- ---------- -------
-7.3
+14.3 0.7 ; -0.2 ; +20.3 1.9 ; +4.7 -5.5 ;
25 mg 6 (0.0399) 27.9 (0.9664) 7.1 5 (0.0334) 38.7 (0.3410) 14.8
--------- --- ---------- ------- ---------- ------ --- ---------- ------- ---------- -------
-10.7 -8.2 -8.4
+3.5 ; -0.6 ; +10.9 ; +3.7 -7.0 ;
50 mg 5 (0.6182) 17.6 (0.8749) 7.0 4 (0.2463) 30.2 (0.4745) 14.3
--------- --- ---------- ------- ---------- ------ --- ---------- ------- ---------- -------
-5.5
-15.3 ; -25.5 -11.3;
Placebo 8 -6.5 ; 2.4 -0.8 3.9 4 -11.8 ; 2.0 -3.8 3.8
--------- --- ---------- ------- ---------- ------ --- ---------- ------- ---------- -------
The Phase 1b study achieved its goals for evaluation of QR-010 including
demonstrating safety and tolerability across a range of doses, identified a
dosing window, exhibited uptake of the RNA oligonucleotide into circulation
following inhalation, and demonstrated early signals of clinical efficacy.
"The positive results in the first two clinical trials of QR-010 significantly
increase the confidence that QR-010 has the potential to become an effective
treatment of CF. The improvement in CFQ-R RSS with the supportive FEV1 data as
shown in this Phase 1b trial is very exciting," said Noreen R. Henig, M.D, Chief
Medical Officer at ProQR. "I want to thank the entire CF community including
those living with CF, clinical investigators, scientists, the CF Foundation, the
European CF Society and the US and European therapeutic development networks for
their unwavering commitment."
Partnership with Cystic Fibrosis Foundation Therapeutics (CFFT)
ProQR and CFFT entered into a partnership in 2014 to develop QR-010 for people
with CF due to the F508del mutation. The initial partnership included support
for the Phase 1b trial as well as the NPD proof of concept study that reported
positive results in 2016. Based on the results of the clinical trials of QR-
010, ProQR and CFFT intend to expand the partnership to explore the inhaled
oligonucleotide platform for stop-codon mutations (also called "Class I"
mutations) in CFTR. Stop-codon mutations cannot be targeted with small molecule
potentiator or corrector molecules, and therefore have a high unmet medical
need. ProQR intends to target these mutations using its proprietary
Axiomer® technology, which has shown compelling data in non-clinical studies, to
repair the stop-codon mutations in the RNA, leading to removal of the premature
stop-codon. Approximately 12,000 patients, accounting for 15% of CF patients in
the western world, have a stop-codon mutation leading to a severe form of CF.
"The results of this Phase 1b trial support QR-010's potential to be a
meaningful therapy for people with cystic fibrosis," said Daniel A. de Boer,
Chief Executive Officer at ProQR. "With these results in hand we are designing a
path forward for the development of QR-010, either independently or with a
potential partner. Furthermore we are looking forward to expanding our
partnership with the CFFT to explore the inhaled oligonucleotide platform also
for people that have CF due to stop-codon mutations."
About the PQ-010-001 Trial
The Phase 1b study was a trial designed to assess safety, tolerability and
pharmacokinetics of QR-010. A number of exploratory efficacy endpoints were
assessed in the multiple dose groups. A total of 4 dose levels were studied:
6.25, 12.5, 25 and 50 mg of QR-010 in solution per dose administered via
inhalation using the PARI eFlow® nebulizer. Subjects eligible to participate
were males and females of 18 years and over with a ppFEV1 of greater than or
equal to 70% at time of inclusion, homozygous for the F508del mutation, and not
taking CFTR modulator drugs. The study design planned to enroll 8 cohorts of 8
subjects (6 receiving QR-010, 2 receiving placebo). In cohorts 1-4, a single
dose of QR-010 was administered, and in cohorts 5-8 twelve doses of QR-010 were
administered over a 4-week period.
QR-010 Milestones
* Technology for QR-010 in-licensed from Massachusetts General Hospital in
2012.
* Partnership with the CFF established to develop QR-010 for patients with the
F508del mutation.
* In vitro proof of concept in three F508del CF assays.
* In vivo proof of concept in two assays, including nasal potential difference
(NPD).
* Pre-clinical in vitro and in vivo proof of concept established for efficient
inhaled delivery to the CF diseased lung in collaboration with the
University of North Carolina at Chapel Hill.
* QR-010 granted fast-track status by the FDA and orphan drug designation from
FDA and the European Commission.
* Program received funding from the European Union's Horizon 2020 research and
innovation programme.
* Clinical trial PQ-010-002 top-line data shows significant improvement of
CFTR function as measured by NPD in subjects homozygous for the F508del
mutation following topical administration of QR-010.
* Grant of two key patents, protecting QR-010 in the US and Europe.
* Preliminary top-line data from clinical trial PQ-010-001 shows QR-010 is
detected in the blood after inhaled administration, was observed to be safe
and well-tolerated and shows signals of efficacy.
* Full data for PQ-010-001 will be presented at the NACFC (November
2-4, 2017).
Conference Call and Webcast Information
ProQR will host a conference call and webcast today at 5:00 PM Eastern Time (ET)
or 11:00 PM Central European Time (CET). The conference call will be webcast
live and a link to the webcast can be accessed through ProQR's website
(www.proqr.com) and in the "Investors" section under "Events and Presentations".
To ensure a timely connection, it is recommended that users register at least
15 minutes prior to the scheduled webcast. An archived webcast will be available
on the company's website. To participate in the conference call, please dial in
5-10 minutes prior to start time and reference Conference ID 8468989:
--------------------------------------------------------------------------
Country Toll Free Direct
------------------ ------------------ ------------------------
US 1 877 280 2296 +1 646 254 3365
------------------ ------------------ ------------------------
Netherlands 0800 020 2576 +31 (0) 20 713 2789
------------------ ------------------ ------------------------
United Kingdom 0800 279 4977 +44 (0) 20 3427 1919
------------------ ------------------ ------------------------
Germany 0800 589 2674 +49 (0) 69 2222 10620
------------------ ------------------ ------------------------
Belgium 0800 58032 +32 (0) 2 400 3463
------------------ ------------------ ------------------------
Switzerland 0800 345 603 +41 (0) 44 580 7214
------------------ ------------------ ------------------------
France 0805 631 580 +33 (0) 1 7677 2222
------------------ ------------------ ------------------------
About QR-010
QR-010 is a first-in-class RNA-based oligonucleotide designed to address the
underlying cause of the disease by targeting the mRNA in CF patients that have
the F508del mutation. The technology was exclusively licensed from Massachusetts
General Hospital. The F508del mutation results in the production of a misfolded
CFTR protein that does not function normally. QR-010 is a single agent designed
to bind to the defective CFTR mRNA and to restore CFTR function. QR-010 is
designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma
GmbH). eFlow® is a small, handheld aerosol delivery device which nebulizes QR-
010 into a mist inhaled directly into the lungs. QR-010 has been granted orphan
drug designation in the United States and the European Union and fast-track
status by the FDA. The QR-010 project received funding from the European Union's
Horizon 2020 research and innovation programme under grant agreement No 633545.
About Cystic Fibrosis
Cystic fibrosis (CF) is the most common fatal inherited disease in the Western
world and affects over 75,000 patients worldwide. In people with CF, a defective
CFTR gene causes a thick buildup of mucus in the lungs, pancreas and other
organs. In the lungs, the mucus clogs the airways and traps bacteria leading to
infections, extensive lung damage and eventually, respiratory failure. There is
no cure for CF. Disease manifestations lead to a shortened life expectancy with
a median age of death of 30 years. Although over 1,900 CF-causing gene mutations
have been identified, approximately 85% of all CF patients are affected by the
F508del mutation. Among all CF patients, approximately 50% are homozygous for
the F508del mutation.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of
transformative RNA medicines for the treatment of severe genetic rare diseases
such as cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic
epidermolysis bullosa. Based on our unique proprietary RNA repair platform
technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements, which are
often indicated by terms such as "anticipate," "believe," "could," "estimate,"
"expect," "goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar expressions.
Forward-looking statements are based on management's beliefs and assumptions and
on information available to management only as of the date of this press
release. These forward-looking statements include, but are not limited to,
statements regarding QR-010, including its clinical development and therapeutic
potential, including future development plans, and statements regarding the
partnership with CFFT. Our actual results could differ materially from those
anticipated in these forward-looking statements for many reasons, including,
without limitation, risks associated with our clinical development activities,
including that positive results observed in our prior and ongoing studies may
not be replicated in later trials or guarantee approval of any product candidate
by regulatory authorities, that a Fast Track designation by the FDA may not
actually lead to a faster development, regulatory review or approval process,
and that we may not be able to realize the potential benefits of orphan drug
exclusivity, manufacturing processes and facilities, regulatory oversight,
product commercialization, intellectual property claims, and the risks,
uncertainties and other factors in our filings made with the Securities and
Exchange Commission, including certain sections of our annual report filed on
Form 20-F. Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new information
becomes available in the future.
ProQR Therapeutics N.V.:
Media Contact:
Sariette Witte
T: +31 6 2970 4513 (NL)
T: + 1 213 261 8891 (US)
pr(at)proqr.com
Investor Contact:
Bonnie Ortega
T: +1 858 245 3983
ir(at)proqr.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProQR Therapeutics N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 25.09.2017 - 22:00 Uhr
Sprache: Deutsch
News-ID 561187
Anzahl Zeichen: 21748
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis"
steht unter der journalistisch-redaktionellen Verantwortung von
ProQR Therapeutics N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
